[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-varices\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-varices":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,83,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100054285","cyanoacrylate-glue-versus-absorbable-gelatin-sponge-for-gastric-varices-100054285",false,"NCT07699354","Cyanoacrylate Glue Versus Absorbable Gelatin Sponge for Gastric Varices","Cyanoacrylate Glue Versus Absorbable Gelatin Sponge for Endoscopic Treatment of Gastric Varices (CoAGS-GV): A Randomized, Patient- and Assessor-Blinded, Non-Inferiority Trial","CoAGS-GV","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Gastric varices deemed suitable for EUS-guided endoscopic treatment.\n* History of suspected gastric variceal bleeding or active gastric variceal bleeding, with treatment intended for secondary prophylaxis.\n* Ability to provide informed consent directly or through a substitute decision maker.\n* Willingness and ability to undergo clinical follow-up, EUS assessment, and CT imaging.\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent directly or through a substitute decision maker.\n* No gastric varix present, or gastric varix too small or not amenable to combination therapy.\n* Contraindication to therapeutic EUS or endoscopy.\n* Contraindication to any study material used in the assigned treatment arm.\n* Contraindication to contrast-enhanced CT, if not clinically manageable.\n* Inability to complete planned follow-up.\n* Pregnancy.\n* Any clinical situation in which the treating endoscopist determines that randomization would be unsafe or inappropriate.","ALL","18 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study compares two endoscopic ultrasound-guided treatments for gastric varices, which are enlarged veins in the stomach that can bleed. Both treatments use small coils placed into the varix. One group will receive coils with cyanoacrylate medical glue, and the other group will receive coils with absorbable gelatin sponge.\n\nThe purpose of the study is to determine whether absorbable gelatin sponge with coils is not worse than cyanoacrylate glue with coils for closing off gastric varices, and to compare safety outcomes. Participants will be randomly assigned to one of the two treatment groups. Participants and outcome assessors will not know which treatment was used, but the doctor performing the procedure will know.\n\nAfter the procedure, participants will be followed for up to 12 months. Follow-up may include clinical assessments, questionnaires about health and quality of life, CT imaging shortly after the procedure, and repeat endoscopic ultrasound assessments to evaluate whether the gastric varix has been successfully treated.",[27,28,29],"Gastric Varices Bleeding","Gastric Varices","Portal Hypertension",[31,32,33,34,35,36,37,38,39],"Endoscopic ultrasound","EUS-guided therapy","Portal hypertension","Cyanoacrylate glue","Absorbable gelatin sponge","Gelfoam","Coil embolization","Variceal obliteration","Secondary prophylaxis","NOT_YET_RECRUITING","2026-07-09",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":21},"2026-08-01",{"date":48,"type":21},"2029-08-01",{"name":50,"class":51},"Unity Health Toronto","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100605889","pre-emptive-rto-for-an-early-detected-gastric-varices-in-ctmr-angiogram-trial-100605889","NCT07168395","Pre-emptive RTO for An Early Detected Gastric Varices in CT\u002FMR Angiogram Trial","Pre-emptive RTO for An Early Detected Gastric Varices in CT\u002FMR Angiogram Trial (PRADA Trial)","PRADA","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Patients with compensated cirrhosis with a higher risk of decompensation based on AASLD 2023 Practice Guidance (Kaplan et al) - no ascites with endoscopic visualization of varices\n3. Confirmed diagnosis of gastric varices either through CT, MRI, or Endoscopy.\n4. No imaging (LIRAD4 or 5) or tumor marker (AFP) evidence of HCC or other malignancy\n5. MELD \\\u003C 20\n6. First de novo RTO procedure\n7. Taking NSBB\n8. Patent internal jugular or right common femoral vein\n9. Willing to provide the hepatology service information for F\u002FU\n10. No known diagnosis of hypercoagulopathy\n11. Patent portal vein or portal vein cavernous transformation\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Patients with decompensated cirrhosis based on AASLD 2023 Practice Guidance (Kaplan et al)\n3. Cardiac failure\n4. Active variceal bleeding\n5. History of gastroesophageal variceal bleeding\n6. Previous TIPS, BRTO, CARTO or PARTO procedure\n7. No right jugular or right common femoral venous access\n8. No portal vein flow\n9. Malignancy\n10. Life expectancy of less than 6 months",{"count":62,"type":21},68,[24],"A number of treatment modalities are currently in use for gastric variceal bleeding (GVB). Balloon-occluded, plug-assisted, and coil-assisted retrograde transvenous obliteration (RTO) procedures are described in the literature as treatments for GVB after a bleeding episode occurs. Preliminary data suggests that prophylactic treatment of gastric varices may improve patient outcomes compared to conservative management. This study aims to compare pre-emptive treatment of gastric varices with current recommended medical management in a randomized prospective study design. Eligible patients will be randomized to receive RTO or to continue conservative management. Patients will be followed for up to 2 years for comparison of clinical outcomes, including episodes of gastric variceal bleeding, overall survival and transplant-free survival, complications, and secondary interventions.",[28],[67,68,69,70,71,72,73],"varices","stomach","gastric","hepatic encephalopathy","gastric variceal bleeding","bleeding","retrograde transvenous obliteration","2026-07-01",{"date":76,"type":44},"2026-07-02",{"date":78,"type":21},"2026-10",{"date":80,"type":21},"2028-11",{"name":82,"class":51},"University of California, Los Angeles",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":104,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100642579","case-specific-health-care-professional-clinical-survey-for-concerto-versa-detachable-coils-100642579","NCT07639853","Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils","Inclusion Criteria:\n\n1. Patient treated with Concerto Versa™ Detachable Coil is age ≥ 22 years at the time of procedure.\n2. Use of Concerto Versa™ Detachable Coil in accordance with the device labeling.\n3. Reporting of case within 72 hours of index procedure.","22 Years",{"count":91,"type":21},30,"OBSERVATIONAL","The purpose of the Case-Specific Health Care Professional (HCP) Clinical Survey for Concerto Versa™ Detachable Coils, also known as the Concerto Versa HCP Clinical Assessment, is to collect early clinical data from HCPs to assess clinical safety and performance of the Concerto Versa™ Detachable Coils, when used in accordance with approved device labeling per the Instructions for Use (IFU). Data collected will generate clinical evidence to quantitatively assess clinical safety and device performance for the purpose of obtaining European Union Medical Device Regulation (EU MDR) approval.",[95,96,28,97,98,99,100,101,102,103],"Arteriovenous Malformation","Gastrointestinal Bleed","Hemorrhoid","Pelvic Venous Disorders","Peripheral Aneurysms","Portal Vein Embolization","Type II Endoleak","Varicocele","Hemorrhage",[105,106,107,108,109,110,111,112,113],"Peripheral Vascular Disease","Vascular Disease","Arterial Embolization","Arteriovenous Embolization","Venous Embolization","Embolization Coils","Peripheral Embolization Coils","Peripheral Arterial Disease","Embolization","2026-06-11",{"date":116,"type":44},"2026-06-15",{"date":118,"type":21},"2026-07",{"date":120,"type":21},"2026-11",{"name":122,"class":123},"Medtronic Endovascular","INDUSTRY",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":92,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100631595","optimizing-endoscopic-and-interventional-treatment-for-portal-hypertensive-bleeding-100631595","NCT07502729","Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding","Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension","Inclusion Criteria:\n\n* Admitted due to gastrointestinal bleeding and clinically diagnosed with portal hypertension\n* Underwent imaging examinations and gastroscopy within one week after admission\n* Gastroscopy revealed the presence of esophageal and\u002For gastric varices\n* Age over 18 years\n\nExclusion Criteria:\n\n* Previous history of liver transplantation\n* Imaging or gastroscopy findings indicated ulcers or other causes of gastrointestinal bleeding\n* Concurrent severe life-threatening diseases involving the circulatory, hematological, or respiratory systems\n* Difficulty in follow-up, or lack of essential medical history information, imaging data, or other necessary records",{"count":132,"type":21},1066,"12 Months","This study aims to evaluate the impact of high-risk factors-such as elevated portal venous pressure, concurrent large extra-luminal vessels, portal vein thrombosis, and prominent portosystemic shunts-on the efficacy of endoscopic therapy. By comparing with interventional treatment, the goal is to optimize the clinical management protocol for esophageal and gastric varices, enhance the therapeutic outcomes of portal hypertension-related esophageal and gastric varices, and improve patient prognosis.",[29,136,28,137],"Gastroesophageal Varices Hemorrhage","Esophageal Varices","2026-03-24",{"date":140,"type":44},"2026-03-31",{"date":142,"type":21},"2026-03-17",{"date":144,"type":21},"2027-12-31",{"name":146,"class":51},"Shanghai Zhongshan Hospital"]